1. An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. (November 2018) Authors: Arkenau, H.-T.; Italiano, A.; Mak, G.; Toulmonde, M.; Baird, R.D.; Garcia-Corbacho, J.; Plummer, R.; Flynn, M.; Forster, M.; Wilson, R.H.; Tosi, D.; Adenis, A.; Donaldson, K.; Posner, J.; Kawabata, I.; Arimura, A.; Deva, S.; Spicer, J. Journal: European journal of cancer Issue: Volume 103(2018) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Author reply. Issue 2 (February 2014) Authors: Wong, S. F.; Mak, G.; Rosenthal, M. A.; Cher, L.; Gan, H. K. Journal: Internal medicine journal Issue: Volume 44:Issue 2(2014) Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Local perspective on a rare brain tumour: adult medulloblastoma. Issue 5 (14th May 2013) Authors: Wong, S. F.; Mak, G.; Rosenthal, M. A.; Cher, L.; Gan, H. K. Journal: Internal medicine journal Issue: Volume 43:Issue 5(2013) Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗